| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/19/2011 | US7927618 Implants, particles |
| 04/19/2011 | US7927613 Pharmaceutical co-crystal compositions |
| 04/19/2011 | CA2624788C Improved testosterone gel and method of use |
| 04/19/2011 | CA2601289C Once-a-day oxycodone formulations |
| 04/19/2011 | CA2598213C Drugs with improved hydrophobicity for incorporation in medical devices |
| 04/19/2011 | CA2596241C Methods and pharmaceutical compositions useful for treating neurological disorders |
| 04/19/2011 | CA2507572C Levalbuterol salt |
| 04/19/2011 | CA2490544C Minimally compliant, volume efficient piston for osmotic drug delivery systems |
| 04/19/2011 | CA2474691C Melt extrusion of salts of active ingredients |
| 04/19/2011 | CA2474674C Solid preparation containing single crystal form |
| 04/19/2011 | CA2462338C Powder processing with pressurized gaseous fluids |
| 04/19/2011 | CA2458452C Gnrh agonist combination drugs |
| 04/19/2011 | CA2452577C Soft capsules |
| 04/19/2011 | CA2428720C Process for enrobing a core |
| 04/19/2011 | CA2425271C Liposomes encapsulating anticancerous drugs and use thereof in the treatment of malignant tumours |
| 04/19/2011 | CA2400886C Novel galenical form for oral administration with prolonged release of molsidomine |
| 04/19/2011 | CA2385659C Novel antiarrhythmic peptides |
| 04/16/2011 | CA2735344A1 A novel formulation for treating fungal infections |
| 04/14/2011 | WO2011044545A2 Methods and compositions for targeted imaging |
| 04/14/2011 | WO2011044540A1 Topical formulation comprising etoricoxib and a zwitterionic surfactant |
| 04/14/2011 | WO2011044533A2 Coating system and method for drug elution management |
| 04/14/2011 | WO2011044516A2 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 04/14/2011 | WO2011044367A1 Methods and compositions for skin regeneration |
| 04/14/2011 | WO2011044207A2 Compositions containing a high concentration of polar sphingolipid(s) |
| 04/14/2011 | WO2011044175A2 Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| 04/14/2011 | WO2011044034A1 Carrageenan-containing aqueous antimicrobial compositions |
| 04/14/2011 | WO2011044008A1 Low ether composition and delivery apparatus |
| 04/14/2011 | WO2011043918A2 Method of forming prolonged-release injectable steroids |
| 04/14/2011 | WO2011043736A1 A passive drug delivery device |
| 04/14/2011 | WO2011043670A1 Amino acid composition with improved dispersibility |
| 04/14/2011 | WO2011043647A1 Amino acid composition with improved dispersibility |
| 04/14/2011 | WO2011043532A1 Lipid nanoparticles for oral administration, and method for preparing same |
| 04/14/2011 | WO2011043455A1 Orally administrable liquid formulation containing acetaminophen |
| 04/14/2011 | WO2011043370A1 Coating film, and granules and tablets each utilizing same |
| 04/14/2011 | WO2011042913A1 Transdermal therapeutic system |
| 04/14/2011 | WO2011042897A1 Liquid precursor compositions and uses thereof for a ph-dependant sustained release treatment of oral disorders |
| 04/14/2011 | WO2011042568A2 Device and method for reversible office sterilization |
| 04/14/2011 | WO2011042542A1 Formulation of drugs and vaccines in the form of percutaneous injectable needles |
| 04/14/2011 | WO2011042485A1 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| 04/14/2011 | WO2011042469A1 Use of a compound based on eremophilanolides |
| 04/14/2011 | WO2011042463A2 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
| 04/14/2011 | WO2011042453A1 Subcutaneous paliperidone composition |
| 04/14/2011 | WO2011042420A1 Delivery system for sustained release of a calcium -channel blocking agent |
| 04/14/2011 | WO2011042156A1 Pharmaceutical compositions comprising rivaroxaban |
| 04/14/2011 | WO2011042077A2 Transdermal therapeutic systems containing 4-n-butylresorcinol |
| 04/14/2011 | WO2011041938A1 Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof |
| 04/14/2011 | WO2011041872A1 Nitric oxide amino acid ester compounds for the prophylaxis of angina pectoris |
| 04/14/2011 | WO2011041865A1 Pharmaceutical composition containin an apitoxin fraction and use thereof |
| 04/14/2011 | WO2011027365A9 Ophthalmic compositions containing dorzolamide, timolol and brimonidine |
| 04/14/2011 | WO2011026234A8 Clarithromycin extended-release tablet |
| 04/14/2011 | WO2011020866A3 Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| 04/14/2011 | WO2011020023A3 Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| 04/14/2011 | WO2011015634A3 Controlled release formulations of lipocalin muteins |
| 04/14/2011 | WO2011006508A3 Adhesive patch with enzyme |
| 04/14/2011 | WO2011002161A3 Transdermal composition comprising tolterodine |
| 04/14/2011 | WO2010150262A3 Reverse hexagonal mesophases (hii) and uses thereof |
| 04/14/2011 | WO2010146179A3 Solid pharmaceutical composition comprising rivaroxaban |
| 04/14/2011 | WO2010138862A3 Compositions for respiratory delivery of active agents and associated methods and systems |
| 04/14/2011 | WO2010137855A3 Multi-layer tablet comprising effervescent layer |
| 04/14/2011 | WO2010131907A3 Sirna delivery system using self-assembled polymeric nanoparticles |
| 04/14/2011 | WO2010106050A9 A particle stabilised oil-in-water emulsion |
| 04/14/2011 | WO2010094806A3 Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
| 04/14/2011 | WO2010093873A3 Drug delivery through hydrogel plugs |
| 04/14/2011 | WO2010084088A3 Starch nanoparticles for drug delivery systems |
| 04/14/2011 | WO2010065730A3 Pharmaceutical suspension |
| 04/14/2011 | WO2010060635A3 Solid pharmaceutical composition comprising at least one stabilizing agent |
| 04/14/2011 | WO2010041256A3 A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same |
| 04/14/2011 | WO2010028489A8 Starch-based microparticles for the release of agents disposed therein |
| 04/14/2011 | US20110087153 Transdermal Methods And Systems For The Delivery Of Rizatriptan |
| 04/14/2011 | US20110087152 Fluidic tissue augmentation compositions and methods |
| 04/14/2011 | US20110087009 Process for the controlled production of organic particles |
| 04/14/2011 | US20110086844 Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance |
| 04/14/2011 | US20110086827 Combination medicament |
| 04/14/2011 | US20110086826 Liposomal camptothecins and uses thereof |
| 04/14/2011 | US20110086801 Prevention and reduction of blood loss |
| 04/14/2011 | US20110086104 Residual solvent extraction method and microparticles produced thereby |
| 04/14/2011 | US20110086103 Novel mandelate salt of fesoterodine |
| 04/14/2011 | US20110086102 Delayed release compositions |
| 04/14/2011 | US20110086101 Dispersinb, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K-Based Antibiofilm Compositions and Uses Thereof |
| 04/14/2011 | US20110086100 Polyethylene Glycol Aerogels for Targeted Delivery of Pharmaceutical Drubs |
| 04/14/2011 | US20110086099 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 04/14/2011 | US20110086098 Rapidly disintegrating gelatinous coated tablets |
| 04/14/2011 | US20110086097 Manufacture process for the preparation of an iron containing phosphate adsorbent |
| 04/14/2011 | US20110086096 Modified release 1- [ (3-hydroxy-adamant-1-ylamino)-acetyl] -pyrrolidine-2 (s) -carbonitrile formulation |
| 04/14/2011 | US20110086095 Bioadhesive Polymers |
| 04/14/2011 | US20110086094 Capsule for the prevention of cardiovascular diseases |
| 04/14/2011 | US20110086093 Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| 04/14/2011 | US20110086092 Pharmacuetical tablets containing a plurality of active ingredients |
| 04/14/2011 | US20110086091 Stable crystal modifications of dopc |
| 04/14/2011 | US20110086090 Vectors Containing the Max Gene |
| 04/14/2011 | US20110086089 Use of p27kip1 for the prevention and treatment of heart failure |
| 04/14/2011 | US20110086088 Compositions and methods for treatment of mammalian skin |
| 04/14/2011 | US20110086087 Process and Formulation for Immunizing Fish in Aquaculture Systems |
| 04/14/2011 | US20110086086 Transdermal system for varenicline |
| 04/14/2011 | US20110086085 Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same |
| 04/14/2011 | US20110086084 Active Agent Containing Polymer Network Delivery Composition and Articles Using the Same |
| 04/14/2011 | US20110086080 Ex-vivo production of human demineralized bone matrix |
| 04/14/2011 | US20110086079 Methods for Producing Hair Microfollicles and De Novo Papillae and Their Use for In Vitro Tests and In Vivo Implantations |
| 04/14/2011 | US20110086074 Combinations of niacin and an oxicam |
| 04/14/2011 | US20110086073 NANOMETER-SIZED PRODRUGS OF NSAIDs |